Effects of a Combined Supplementation of Conjugated Linoleic Acid (CLA) and Probiotics (Vivomixx®) as add-on to a First-line Immunotherapy in Relapsing-remitting Multiple Sclerosis

This study is testing whether taking two dietary supplements — conjugated linoleic acid (CLA, a fatty acid found in dairy) and a probiotic called Vivomixx — alongside standard first-line immune-modifying medications can help reduce relapses in people with relapsing-remitting multiple sclerosis (RRMS). RRMS is the most common form of MS, where periods of worsening symptoms are followed by recovery. **You may be eligible if:** - You have relapsing-remitting multiple sclerosis (RRMS) diagnosed according to current guidelines - You have a disability level (EDSS score) of 5.5 or lower - You are 18–60 years old - You have been on a stable first-line MS treatment (interferon-beta, teriflunomide, or glatiramer acetate) for at least 6 months - You have not had a relapse in the past 3 months **You may NOT be eligible if:** - You have primary or secondary progressive MS - You have taken stronger MS medications such as natalizumab, fingolimod, ocrelizumab, or alemtuzumab recently - You are already taking dietary supplements (vitamins, probiotics, omega-3 fatty acids, etc.) - You have significant gut problems (such as inflammatory bowel disease) - You are pregnant or breastfeeding - You follow a strictly vegan diet (which may affect supplement absorption) Talk to your doctor to see if this trial is right for you.